Mylan reforms plant as it ponders options

Mylan is overhauling its large-scale US manufacturing plant in Morgantown, West Virginia, and discontinuing several products in a bid to reduce complexity and improve its competitiveness. And with US market uptake of complex products such as generic Copaxone (glatiramer acetate) disappointing, the company has slashed the topend of its full-year turnover forecast by US$1.0 billion to US$12.25 billion as a board-level committee starts considering “all alternatives to unlock value” (Generics bulletin, 10 August 2018, page 1).

Having committed to “a robust improvement plan” in response to a 32-page ‘Form 483’ list of observations and deficiencies issued...